{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T19:34:41Z","timestamp":1790883281942,"version":"4.1.0"},"reference-count":209,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T00:00:00Z","timestamp":1744243200000},"content-version":"vor","delay-in-days":99,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revista de Gastroenterolog\u00eda de M\u00e9xico (English Edition)"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.rgmxen.2024.10.009","type":"journal-article","created":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T11:27:58Z","timestamp":1745926078000},"page":"77-110","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Pharmacologic treatment of irritable bowel syndrome. Position statement of the Asociaci\u00f3n Mexicana de Gastroenterolog\u00eda, 2024"],"prefix":"10.1016","volume":"90","author":[{"given":"J.M.","family":"Remes-Troche","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Coss-Adame","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Schmulson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.R.","family":"Garc\u00eda-Zerme\u00f1o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Amieva-Balmori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Carmona-S\u00e1nchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"G\u00f3mez-Escudero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.C.","family":"G\u00f3mez-Casta\u00f1os","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.E.","family":"Icaza-Ch\u00e1vez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"L\u00f3pez-Colombo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.C.","family":"Morel-Cerda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.\u00c1.","family":"Valdovinos-D\u00edaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.R.","family":"Valdovinos-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.S.","family":"Villar-Ch\u00e1vez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.rgmxen.2024.10.009_bib0005","article-title":"Bowel disorders","author":"Mearin","year":"2016","journal-title":"Gastroenterology."},{"key":"10.1016\/j.rgmxen.2024.10.009_bib0010","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S2468-1253(16)30023-1","article-title":"Pathophysiology of irritable bowel syndrome","volume":"1","author":"Holtmann","year":"2016","journal-title":"Lancet Gastroenterol Hepatol."},{"key":"10.1016\/j.rgmxen.2024.10.009_bib0015","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2020.04.014","article-title":"Worldwide Prevalence and Burden of Functional Gastrointestinal Disorders, Results of Rome Foundation Global Study","volume":"160","author":"Sperber","year":"2021","journal-title":"Gastroenterology."},{"key":"10.1016\/j.rgmxen.2024.10.009_bib0020","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/606174","article-title":"The epidemiology of functional gastrointestinal disorders in Mexico: a population-based study","volume":"2012","author":"L\u00f3pez-Colombo","year":"2012","journal-title":"Gastroenterol Res Pract."},{"key":"10.1016\/j.rgmxen.2024.10.009_bib0025","doi-asserted-by":"crossref","first-page":"S","DOI":"10.1016\/S0016-5085(14)61937-5","article-title":"Prevalence of Irritable Bowel Syndrome in Mexico. A Nationwide Population Based Study Using the ROME III Questionnaire","volume":"146","author":"Amieva-Balmori","year":"2014","journal-title":"Gastroenterology."},{"key":"10.1016\/j.rgmxen.2024.10.009_bib0030","doi-asserted-by":"crossref","first-page":"e5836","DOI":"10.1136\/bmj.e5836","article-title":"Irritable bowel syndrome","volume":"345","author":"Ford","year":"2012","journal-title":"BMJ."},{"key":"10.1016\/j.rgmxen.2024.10.009_bib0035","first-page":"42","article-title":"Tratamiento farmacol\u00f3gico del s\u00edndrome de intestino irritable: revisi\u00f3n t\u00e9cnica","volume":"75","author":"Remes-Troche","year":"2010","journal-title":"Rev Gastroenterol Mex."},{"key":"10.1016\/j.rgmxen.2024.10.009_bib0040","first-page":"S41","article-title":"Tratamiento farmacol\u00f3gico de pacientes con s\u00edndrome de intestino irritable","volume":"33","author":"G\u00f3mez-Escudero","year":"2017","journal-title":"Med Int M\u00e9x."},{"key":"10.1016\/j.rgmxen.2024.10.009_bib0045","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1136\/gutjnl-2016-313425","article-title":"Dietary and pharmacological treatment of abdominal pain in IBS","volume":"66","author":"Camilleri","year":"2017","journal-title":"Gut."},{"key":"10.1016\/j.rgmxen.2024.10.009_bib0050","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.14309\/ajg.0000000000001266","article-title":"Antispasmodics for chronic abdominal pain: analysis of North American treatment options","volume":"116","author":"Brenner","year":"2021","journal-title":"Am J Gastroenterol."},{"key":"10.1016\/j.rgmxen.2024.10.009_bib0055","first-page":"3","article-title":"Muscarinic receptor subtypes in the alimentary tract","volume":"60","author":"Tobin","year":"2009","journal-title":"J Physiol Pharmacol."},{"key":"10.1016\/j.rgmxen.2024.10.009_bib0060","first-page":"1262","article-title":"Oral cimetropium bromide, a new antimuscarinic drug, for long-term treatment of irritable bowel syndrome","volume":"83","author":"Centoze","year":"1988","journal-title":"Am J Gastroenterol."},{"key":"10.1016\/j.rgmxen.2024.10.009_bib0065","doi-asserted-by":"crossref","first-page":"3561","DOI":"10.2174\/1381612043382972","article-title":"Quaternary ammonium derivates as spasmolytics for irritable bowel syndrome","volume":"10","author":"Evangelista","year":"2004","journal-title":"Curr Pharm Des."},{"key":"10.1016\/j.rgmxen.2024.10.009_bib0070","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.2174\/1381612824666180507122935","article-title":"Otilonium bromide: a drug with a complex mechanism of action","volume":"24","author":"Evangelista","year":"2018","journal-title":"Curr Pharm Des."},{"key":"10.1016\/j.rgmxen.2024.10.009_bib0075","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1136\/flgastro-2019-101298","article-title":"Best management of irritable bowel syndrome","volume":"12","author":"Black","year":"2021","journal-title":"Front Gastroenterol."},{"key":"10.1016\/j.rgmxen.2024.10.009_bib0080","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/nrgastro.2012.207","article-title":"New treatments for IBS","volume":"10","author":"Halland","year":"2013","journal-title":"J Nat Rev Gastroenterol Hepatol."},{"key":"10.1016\/j.rgmxen.2024.10.009_bib0085","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41395-018-0084-x","article-title":"American College of Gastroenterology Monograph on management of irritable bowel syndrome","volume":"113","author":"Ford","year":"2018","journal-title":"Am J Gastroenterol."},{"key":"10.1016\/j.rgmxen.2024.10.009_bib0090","unstructured":"US., Department of Health, Human Services, Food, Drug Administration, Center for Drug Evaluation, Research. Guidance for Industry: irritable bowel syndrome \u2013 clinical evaluation of drugs for treatment. 2012 [accessed 20 Jun 2023]. Available from: http:\/\/www.fda.gov\/download\/Drugs\/Gudances\/UCM205269.pdf."},{"key":"10.1016\/j.rgmxen.2024.10.009_bib0095","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1111\/j.1365-2036.2006.02938.x","article-title":"Systematic review: the efficacy of treatments for irritable bowel syndrome \u2013 a European perspective","volume":"24","author":"Tack","year":"2006","journal-title":"Aliment Pharmacol Ther."},{"key":"10.1016\/j.rgmxen.2024.10.009_bib0100","doi-asserted-by":"crossref","first-page":"a2313","DOI":"10.1136\/bmj.a2313","article-title":"Effect of fiber, antispasmodics, and peppermint oil in irritable bowel syndrome: systematic review and meta-analysis","volume":"337","author":"Ford","year":"2008","journal-title":"BMJ."},{"key":"10.1016\/j.rgmxen.2024.10.009_bib0105","article-title":"Bulking agents, antispasmodics and antidepressants for the treatment of irritable bowel syndrome","volume":"10","author":"Ruepert","year":"2011","journal-title":"Cochrane Database Syst Rev."},{"key":"10.1016\/j.rgmxen.2024.10.009_bib0110","first-page":"82","article-title":"Effect of antispasmodic agents, alone or in combination, in the treatment of Irritable Bowel Syndrome: systematic review and meta-analysis","volume":"77","author":"Mart\u00ednez-V\u00e1zquez","year":"2012","journal-title":"Rev Gastroenterol Mex."},{"key":"10.1016\/j.rgmxen.2024.10.009_bib0115","doi-asserted-by":"crossref","first-page":"6031","DOI":"10.3748\/wjg.v20.i20.6031","article-title":"Role of antispasmodics in the treatment of irritable bowel syndrome","volume":"20","author":"Annah\u00e1zi","year":"2014","journal-title":"World J Gastroenterol."},{"key":"10.1016\/j.rgmxen.2024.10.009_bib0120","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S2468-1253(19)30324-3","article-title":"Efficacy of soluble fibre, antispasmodic drugs, and gut-brain neuromodulators in irritable bowel syndrome: a systematic review and network meta-analysis","volume":"5","author":"Black","year":"2020","journal-title":"Lancet Gastroenterol Hepatol."},{"key":"10.1016\/j.rgmxen.2024.10.009_bib0125","first-page":"149","article-title":"Consenso mexicano sobre el s\u00edndrome de intestino irritable","volume":"81","author":"Carmona-S\u00e1nchez","year":"2016","journal-title":"Rev Gastroenterol Mex."},{"key":"10.1016\/j.rgmxen.2024.10.009_bib0130","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1177\/096032719601501004","article-title":"Research into individual predisposition to develop acute rhabdomyolysis attributed to fenoverine","volume":"15","author":"Jouglard","year":"1996","journal-title":"Hum Exp Toxicol."},{"key":"10.1016\/j.rgmxen.2024.10.009_bib0135","first-page":"619","article-title":"Handbook of pharmaceutical excipients","volume":"6","author":"Rowe","year":"2009","journal-title":"Pharmaceutical Press."},{"key":"10.1016\/j.rgmxen.2024.10.009_bib0140","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1111\/jphp.12021","article-title":"Influence of simethicone and alverine on stress-induced alterations of colonic permeability and sensitivity in rats: beneficial effect of their association","volume":"65","author":"Bueno","year":"2013","journal-title":"J Pharm Pharmacol."},{"key":"10.1016\/j.rgmxen.2024.10.009_bib0145","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1023\/A:1018510626305","article-title":"The carbohydrate moiety of alpha-galactosidase from Trichoderma reesei","volume":"14","author":"Savel\u2019ev","year":"1997","journal-title":"Glycoconj J."},{"key":"10.1016\/j.rgmxen.2024.10.009_bib0150","first-page":"441","article-title":"Does beano prevent gas? A double-blind crossover study of oral alpha-galactosidase to treat dietary oligosaccharide intolerance","volume":"39","author":"Ganiats","year":"1994","journal-title":"J Fam Pract."},{"key":"10.1016\/j.rgmxen.2024.10.009_bib0155","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0149-2918(98)80059-3","article-title":"Effects of beano on the tolerability and pharmacodynamics of acarbose","volume":"20","author":"Lettieri","year":"1998","journal-title":"Clin Ther."},{"key":"10.1016\/j.rgmxen.2024.10.009_bib0160","doi-asserted-by":"crossref","first-page":"e30","DOI":"10.1097\/MCG.0000000000001242","article-title":"Efficacy of the combination of pinaverium bromide 100 mg plus simethicone 300 mg in abdominal pain and bloating in irritable bowel syndrome: a randomized, placebo-controlled trial","volume":"54","author":"Schmulson","year":"2020","journal-title":"J Clin Gastroenterol."},{"key":"10.1016\/j.rgmxen.2024.10.009_bib0165","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1111\/j.1365-2036.2009.04216.x","article-title":"Clinical trial: the efficacy of alverine citrate\/simeticone combination on abdominal pain\/discomfort in irritable bowel syndrome\u2014a randomized, double-blind, placebo-controlled study","volume":"31","author":"Wittmann","year":"2010","journal-title":"Aliment Pharmacol Ther."},{"key":"10.1016\/j.rgmxen.2024.10.009_bib0170","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1111\/ijcp.12333","article-title":"On-demand treatment with alverine citrate\/simeticone compared with standard treatments for irritable bowel syndrome: results of a randomised pragmatic study","volume":"68","author":"Ducrotte","year":"2014","journal-title":"Int J Clin Pract."},{"key":"10.1016\/j.rgmxen.2024.10.009_bib0175","doi-asserted-by":"crossref","first-page":"16","DOI":"10.3109\/00365521.2015.1063156","article-title":"Does oral \u03b1-galactosidase relieve irritable bowel symptoms?","volume":"51","author":"Hillil\u00e4","year":"2016","journal-title":"Scand J Gastroenterol."},{"key":"10.1016\/j.rgmxen.2024.10.009_bib0180","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1038\/ajg.2017.245","article-title":"Increasing symptoms in irritable bowel symptoms with ingestion of galacto-oligosaccharides are mitigated by \u03b1-galactosidase treatment","volume":"113","author":"Tuck","year":"2018","journal-title":"Am J Gastroenterol."},{"key":"10.1016\/j.rgmxen.2024.10.009_bib0185","doi-asserted-by":"crossref","first-page":"S","DOI":"10.1016\/S0016-5085(22)60081-7","article-title":"170: effect of the administration of a combination of trimebutine + simethicone + \u03b1-galactosidase over gas production related symptoms in patients with functional abdominal bloating (fab) under a high fodmap diet","volume":"162","author":"Aja-Cadena","year":"2022","journal-title":"Gastroenterology."},{"key":"10.1016\/j.rgmxen.2024.10.009_bib0190","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/0016-5085(88)90550-1","article-title":"Osmotic effects of polyethylene glycol","volume":"94","author":"Schiller","year":"1988","journal-title":"Gastroenterology."},{"key":"10.1016\/j.rgmxen.2024.10.009_bib0195","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1177\/106002809202601017","article-title":"Lactulose in the management of constipation: a current review","volume":"26","author":"Kot","year":"1992","journal-title":"Ann Pharmacother."},{"key":"10.1016\/j.rgmxen.2024.10.009_bib0200","article-title":"Lactulose versus polyethylene glycol for chronic constipation","volume":"7","author":"Lee-Robichaud","year":"2010","journal-title":"Cochrane Database Syst Rev."},{"key":"10.1016\/j.rgmxen.2024.10.009_bib0205","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1038\/ajg.2013.197","article-title":"Randomized clinical trial: macrogol\/PEG 3350 plus electrolytes for treatment of patients with constipation associated with irritable bowel syndrome","volume":"108","author":"Chapman","year":"2013","journal-title":"Am J Gastroenterol."},{"key":"10.1016\/j.rgmxen.2024.10.009_bib0210","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1053\/j.gastro.2022.04.017","article-title":"AGA Clinical Practice Guideline on the pharmacological management of irritable bowel syndrome with diarrhea","volume":"163","author":"Lembo","year":"2022","journal-title":"Gastroenterology."},{"key":"10.1016\/j.rgmxen.2024.10.009_bib0215","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1007\/BF01296049","article-title":"Effect of lidamidine, a propose alpha 2-adrenoreceptor agonist, on salt and water transport in jejunum","volume":"31","author":"Edwards","year":"1986","journal-title":"Dig Dis Sci."},{"key":"10.1016\/j.rgmxen.2024.10.009_bib0220","doi-asserted-by":"crossref","first-page":"332","DOI":"10.5009\/gnl14397","article-title":"Bile acid diarrhea: prevalence, pathogenesis, and therapy","volume":"9","author":"Camilleri","year":"2015","journal-title":"Gut Liver."},{"key":"10.1016\/j.rgmxen.2024.10.009_bib0225","doi-asserted-by":"crossref","first-page":"2781","DOI":"10.1517\/14656566.2015.1101449","article-title":"Current and emerging drug options in the treatment of diarrhea predominant irritable bowel syndrome","volume":"16","author":"Nee","year":"2015","journal-title":"Expert Opin Pharmacother."},{"key":"10.1016\/j.rgmxen.2024.10.009_bib0230","doi-asserted-by":"crossref","first-page":"77","DOI":"10.3109\/00365528709091003","article-title":"Loperamide in treatment of irritable bowel syndrome\u2013a double-blind placebo controlled study","volume":"130","author":"Lav\u00f6","year":"1987","journal-title":"Scand J Gastroenterol Suppl."},{"key":"10.1016\/j.rgmxen.2024.10.009_bib0235","doi-asserted-by":"crossref","first-page":"81","DOI":"10.3109\/00365528709091004","article-title":"Loperamide treatment of the irritable bowel syndrome","volume":"130","author":"Hovdenak","year":"1987","journal-title":"Scand J Gastroenterol Suppl."},{"key":"10.1016\/j.rgmxen.2024.10.009_bib0240","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1111\/j.1365-2036.1988.tb00728.x","article-title":"Double-blind study of an alpha 2 agonist in the treatment of irritable bowel syndrome","volume":"2","author":"Prior","year":"1988","journal-title":"Aliment Pharmacol Ther."},{"key":"10.1016\/j.rgmxen.2024.10.009_bib0245","first-page":"7","article-title":"Tratamiento del colon irritable con lidamidina y psicoterapia de apoyo","volume":"62","author":"Rodr\u00edguez-Magall\u00e1n","year":"1997","journal-title":"Rev Gastroenterol Mex."},{"key":"10.1016\/j.rgmxen.2024.10.009_bib0250","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/apt.13227","article-title":"Systematic review with meta-analysis: the prevalence of bile acid malabsorption in the irritable bowel syndrome with diarrhoea","volume":"42","author":"Slattery","year":"2015","journal-title":"Aliment Pharmacol Ther."},{"key":"10.1016\/j.rgmxen.2024.10.009_bib0255","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1152\/physrev.00018.2018","article-title":"The microbiota-gut-brain axis","volume":"99","author":"Cryan","year":"2019","journal-title":"Physiol Rev."},{"key":"10.1016\/j.rgmxen.2024.10.009_bib0260","doi-asserted-by":"crossref","first-page":"8137","DOI":"10.3748\/wjg.v22.i36.8137","article-title":"Regulation of the serotonin transporter in the pathogenesis of irritable bowel syndrome","volume":"22","author":"Jin","year":"2016","journal-title":"World J Gastroenterol."},{"key":"10.1016\/j.rgmxen.2024.10.009_bib0265","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1111\/j.1365-2036.2010.04395.x","article-title":"Effects of a 5-HT (3) antagonist, ondansetron, on fasting and postprandial small bowel water content assessed by magnetic resonance imaging","volume":"32","author":"Marciani","year":"2010","journal-title":"Aliment Pharmacol Ther."},{"key":"10.1016\/j.rgmxen.2024.10.009_bib0270","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1016\/S0140-6736(01)07103-3","article-title":"Serotoninergic neuroenteric modulators","volume":"358","author":"Talley","year":"2001","journal-title":"Lancet."},{"key":"10.1016\/j.rgmxen.2024.10.009_bib0275","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1111\/j.1365-2036.2006.02858.x","article-title":"Review article: intestinal serotonin signalling in irritable bowel syndrome","volume":"23","author":"Mawe","year":"2006","journal-title":"Aliment Pharmacol Ther."},{"key":"10.1016\/j.rgmxen.2024.10.009_bib0280","article-title":"Efficacy and safety of 5-hydroxytryptamine 3 receptor antagonists in irritable bowel syndrome: a systematic review and meta-analysis of randomized controlled trials","volume":"12","author":"Zheng","year":"2017","journal-title":"PLoS One."},{"key":"10.1016\/j.rgmxen.2024.10.009_bib0285","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1111\/apt.17426","article-title":"Randomised, placebo-controlled trial and meta-analysis show benefit of ondansetron for irritable bowel syndrome with diarrhoea: the TRITON trial","volume":"57","author":"Gunn","year":"2023","journal-title":"Aliment Pharmacol Ther."},{"key":"10.1016\/j.rgmxen.2024.10.009_bib0290","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1136\/gutjnl-2013-305989","article-title":"A randomised trial of ondansetron for the treatment of irritable bowel syndrome with diarrhoea","volume":"63","author":"Garsed","year":"2014","journal-title":"Gut."},{"key":"10.1016\/j.rgmxen.2024.10.009_bib0295","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.14309\/ajg.0000000000000727","article-title":"Bimodal release ondansetron improves stool consistency and symptomatology in diarrhea-predominant irritable bowel syndrome: a randomized, double-blind, trial","volume":"115","author":"Plasse","year":"2020","journal-title":"Am J Gastroenterol."},{"key":"10.1016\/j.rgmxen.2024.10.009_bib0300","first-page":"453","article-title":"Are symptomatic changes in irritable bowel syndrome correlated with the capsule endoscopy transit time? A pilot study using the 5-HT4 receptor agonist mosapride","volume":"58","author":"Nakamura","year":"2011","journal-title":"Hepatogastroenterology."},{"key":"10.1016\/j.rgmxen.2024.10.009_bib0305","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1111\/j.1365-2982.2011.01732.x","article-title":"Effect of 5-HT4 receptor agonist mosapride citrate on rectosigmoid sensorimotor function in patients with irritable bowel syndrome","volume":"23","author":"Kanazawa","year":"2011","journal-title":"Neurogastroenterol Motil."},{"key":"10.1016\/j.rgmxen.2024.10.009_bib0310","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1111\/nmo.12544","article-title":"Efficacy of combination therapy with probiotics and mosapride in patients with IBS without diarrhea: a randomized, double-blind, placebo-controlled, multicenter, phase II trial","volume":"27","author":"Choi","year":"2015","journal-title":"Neurogastroenterol Motil."},{"key":"10.1016\/j.rgmxen.2024.10.009_bib0315","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1007\/s10151-013-1017-8","article-title":"The association between prucalopride efficacy and constipation type","volume":"17","author":"Jadav","year":"2013","journal-title":"Tech Coloproctol."},{"key":"10.1016\/j.rgmxen.2024.10.009_bib0320","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s12876-016-0556-7","article-title":"Chronic constipation diagnosis and treatment evaluation: the \u201cCHRO.CO. DI. T.E.\u201d study","volume":"17","author":"Bellini","year":"2017","journal-title":"BMC Gastroenterol."},{"key":"10.1016\/j.rgmxen.2024.10.009_bib0325","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/nmo.12217","article-title":"Effect of prucalopride on symptoms of chronic constipation","volume":"26","author":"Tack","year":"2014","journal-title":"Neurogastroenterol Motil."},{"key":"10.1016\/j.rgmxen.2024.10.009_bib0330","doi-asserted-by":"crossref","first-page":"184","DOI":"10.14309\/ajg.0000000000001521","article-title":"Efficacy of prucalopride for chronic idiopathic constipation: an analysis of participants with moderate to very severe abdominal bloating","volume":"117","author":"Staller","year":"2022","journal-title":"Am J Gastroenterol."},{"key":"10.1016\/j.rgmxen.2024.10.009_bib0335","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.2146\/ajhp130575","article-title":"Linaclotide: a novel agent for chronic constipation and irritable bowel syndrome","volume":"71","author":"Love","year":"2014","journal-title":"Am J Health Syst Pharm."},{"key":"10.1016\/j.rgmxen.2024.10.009_bib0340","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/j.lfs.2010.03.015","article-title":"Linaclotide is a potent and selective guanylate cyclase C agonist that elicits pharmacological effects locally in the gastrointestinal tract","volume":"86","author":"Bryant","year":"2010","journal-title":"Life Sci."},{"key":"10.1016\/j.rgmxen.2024.10.009_bib0345","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2013.08.017","article-title":"Linaclotide inhibits colonic nociceptors and relieves abdominal pain via guanylate cyclase-C and extracellular cyclic guanosine 3\u2019,5\u2019-monophosphate","volume":"145","author":"Castro","year":"2013","journal-title":"Gastroenterology."},{"key":"10.1016\/j.rgmxen.2024.10.009_bib0350","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1177\/2040622314567678","article-title":"Lubiprostone in constipation: clinical evidence and place in therapy","volume":"6","author":"Wilson","year":"2015","journal-title":"Ther Adv Chronic Dis."},{"key":"10.1016\/j.rgmxen.2024.10.009_bib0355","doi-asserted-by":"crossref","first-page":"C1173","DOI":"10.1152\/ajpcell.00528.2003","article-title":"SPI-0211 activates T84 cell chloride transport and recombinant human ClC-2 chloride currents","volume":"287","author":"Cuppoletti","year":"2004","journal-title":"Am J Physiol Cell Physiol."},{"key":"10.1016\/j.rgmxen.2024.10.009_bib0360","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1146\/annurev.physiol.62.1.535","article-title":"Chloride secretion by the intestinal epithelium: molecular basis and regulatory aspects","volume":"62","author":"Barrett","year":"2000","journal-title":"Annu Rev Physiol."},{"key":"10.1016\/j.rgmxen.2024.10.009_bib0365","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1517\/17425255.4.8.1091","article-title":"Clinical pharmacology of lubiprostone, a chloride channel activator in defecation disorders","volume":"4","author":"Ginzburg","year":"2008","journal-title":"Expert Opin Drug Metab Toxicol."},{"key":"10.1016\/j.rgmxen.2024.10.009_bib0370","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2010.08.041","article-title":"Linaclotide improves abdominal pain and bowel habits in a phase IIb study of patients with irritable bowel syndrome with constipation","volume":"139","author":"Johnston","year":"2010","journal-title":"Gastroenterology."},{"key":"10.1016\/j.rgmxen.2024.10.009_bib0375","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1038\/ajg.2012.254","article-title":"Linaclotide for irritable bowel syndrome with constipation: a 26-week, randomized, double-blind, placebo-controlled trial to evaluate efficacy and safety","volume":"107","author":"Chey","year":"2012","journal-title":"Am J Gastroenterol."},{"key":"10.1016\/j.rgmxen.2024.10.009_bib0380","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1038\/ajg.2012.255","article-title":"A 12-week, randomized, controlled trial with a 4-week randomized withdrawal period to evaluate the efficacy and safety of linaclotide in irritable bowel syndrome with constipation","volume":"107","author":"Rao","year":"2012","journal-title":"Am J Gastroenterol."},{"key":"10.1016\/j.rgmxen.2024.10.009_bib0385","first-page":"70","article-title":"Efficacy and safety of lubiprostone for the treatment of chronic idiopathic constipation: a phase 3, randomized, placebo-controlled study","volume":"89","author":"Coss-Adame","year":"2024","journal-title":"Rev Gastroenterol Mex (Engl Ed)."},{"key":"10.1016\/j.rgmxen.2024.10.009_bib0390","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1111\/j.1365-2036.2008.03629.x","article-title":"Clinical trial: phase 2 study of lubiprostone for irritable bowel syndrome with constipation","volume":"27","author":"Johanson","year":"2008","journal-title":"Aliment Pharmacol Ther."},{"key":"10.1016\/j.rgmxen.2024.10.009_bib0395","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.mayocp.2016.01.015","article-title":"Lubiprostone is effective in the treatment of chronic idiopathic constipation and irritable bowel syndrome: a systematic review and meta-analysis of randomized controlled trials","volume":"91","author":"Li","year":"2016","journal-title":"Mayo Clin Proc."},{"key":"10.1016\/j.rgmxen.2024.10.009_bib0400","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1136\/gut.2010.227132","article-title":"Effect of laxatives and pharmacological therapies in chronic idiopathic constipation: systematic review and meta-analysis","volume":"60","author":"Ford","year":"2011","journal-title":"Gut."},{"key":"10.1016\/j.rgmxen.2024.10.009_bib0405","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1080\/14656566.2018.1494728","article-title":"Linaclotide for the treatment of chronic constipation","volume":"19","author":"Bassotti","year":"2018","journal-title":"Expert Opin Pharmacother."},{"key":"10.1016\/j.rgmxen.2024.10.009_bib0410","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s40265-013-0157-5","article-title":"Linaclotide: a review of its use in the treatment of irritable bowel syndrome with constipation","volume":"74","author":"McCormack","year":"2014","journal-title":"Drugs."},{"key":"10.1016\/j.rgmxen.2024.10.009_bib0415","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1007\/s10620-011-1702-2","article-title":"Lubiprostone for the treatment of adults with constipation and irritable bowel syndrome","volume":"56","author":"Schey","year":"2011","journal-title":"Dig Dis Sci."},{"key":"10.1016\/j.rgmxen.2024.10.009_bib0420","doi-asserted-by":"crossref","first-page":"G942","DOI":"10.1152\/ajpgi.00264.2005","article-title":"Effect of a selective chloride channel activator, lubiprostone, on gastrointestinal transit, gastric sensory, and motor functions in healthy volunteers","volume":"290","author":"Camilleri","year":"2006","journal-title":"Am J Physiol Gastrointest Liver Physiol."},{"key":"10.1016\/j.rgmxen.2024.10.009_bib0425","first-page":"S489","article-title":"Pooled analysis of the most frequent adverse events associated with the use of lubiprostone (abstract)","volume":"101","author":"Ueno","year":"2006","journal-title":"J Gastroenterol."},{"key":"10.1016\/j.rgmxen.2024.10.009_bib0430","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1038\/ja.2014.106","article-title":"Rifaximin: beyond the traditional antibiotic activity","volume":"67","author":"Calanni","year":"2014","journal-title":"J Antibiot (Tokyo)."},{"key":"10.1016\/j.rgmxen.2024.10.009_bib0435","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/apt.13406","article-title":"Introduction: understanding mechanisms of the actions of rifaximin in selected gastrointestinal diseases","volume":"43","author":"DuPont","year":"2016","journal-title":"Aliment Pharmacol Ther."},{"key":"10.1016\/j.rgmxen.2024.10.009_bib0440","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/0732-8893(93)90004-Q","article-title":"Antimicrobial activity and spectrum of rifaximin, a new topical rifamycin derivative","volume":"16","author":"Hoover","year":"1993","journal-title":"Diagn Microbiol Infect Dis."},{"key":"10.1016\/j.rgmxen.2024.10.009_bib0445","doi-asserted-by":"crossref","first-page":"309","DOI":"10.2147\/CEG.S89999","article-title":"Modulation of the gut microbiota composition by rifaximin in non-constipated irritable bowel syndrome patients: a molecular approach","volume":"8","author":"Soldi","year":"2015","journal-title":"Clin Exp Gastroenterol."},{"key":"10.1016\/j.rgmxen.2024.10.009_bib0450","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1159\/000443361","article-title":"The role of antibiotics in gut microbiota modulation: the eubiotic effects of rifaximin","volume":"34","author":"Ponziani","year":"2016","journal-title":"Dig Dis."},{"key":"10.1016\/j.rgmxen.2024.10.009_bib0455","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1004409","article-title":"Rifaximin therapy for patients with irritable bowel syndrome without constipation","volume":"364","author":"Pimentel","year":"2011","journal-title":"N Engl J Med."},{"key":"10.1016\/j.rgmxen.2024.10.009_bib0460","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/ajg.2011.355","article-title":"The efficacy and safety of rifaximin for the irritable bowel syndrome: a systematic review and meta-analysis","volume":"107","author":"Menees","year":"2012","journal-title":"Am J Gastroenterol."},{"key":"10.1016\/j.rgmxen.2024.10.009_bib0465","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1053\/j.gastro.2016.08.003","article-title":"Repeat treatment with rifaximin is safe and effective in patients with diarrhea-predominant irritable bowel syndrome","volume":"151","author":"Lembo","year":"2016","journal-title":"Gastroenterology."},{"key":"10.1016\/j.rgmxen.2024.10.009_bib0470","doi-asserted-by":"crossref","DOI":"10.14309\/ctg.0000000000000144","article-title":"Abdominal pain response to rifaximin in patients with irritable bowel syndrome with diarrhea","volume":"11","author":"Lembo","year":"2020","journal-title":"Clin Transl Gastroenterol."},{"key":"10.1016\/j.rgmxen.2024.10.009_bib0475","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1177\/1756283X17726087","article-title":"Repeat treatment with rifaximin improves irritable bowel syndrome-related quality of life: a secondary analysis of a randomized, double-blind, placebo-controlled trial","volume":"10","author":"Cash","year":"2017","journal-title":"Therap Adv Gastroenterol."},{"key":"10.1016\/j.rgmxen.2024.10.009_bib0480","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1136\/gutjnl-2012-302167","article-title":"Intestinal microbiota in functional bowel disorders: a Rome foundation report","volume":"62","author":"Simren","year":"2013","journal-title":"Gut."},{"key":"10.1016\/j.rgmxen.2024.10.009_bib0485","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1038\/nrgastro.2014.66","article-title":"The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic","volume":"11","author":"Hill","year":"2014","journal-title":"Nat Rev Gastroenterol Hepatol."},{"key":"10.1016\/j.rgmxen.2024.10.009_bib0490","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.3390\/nu9091021","article-title":"Effects of probiotics, prebiotics, and synbiotics on human health","volume":"9","author":"Markowiak","year":"2017","journal-title":"Nutrients."},{"key":"10.1016\/j.rgmxen.2024.10.009_bib0495","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1111\/j.1365-2036.2008.03853.x","article-title":"Clinical trial: the effects of a fermented milk product containing Bifidobacterium lactis DN\u2010173 010 on abdominal distension and gastrointestinal transit in irritable bowel syndrome with constipation","volume":"29","author":"Agrawal","year":"2009","journal-title":"Aliment Pharmacol Ther."},{"key":"10.1016\/j.rgmxen.2024.10.009_bib0500","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/nm1521","article-title":"Lactobacillus acidophilus modulates intestinal pain and induces opioid and cannabinoid receptors","volume":"13","author":"Rousseaux","year":"2007","journal-title":"Nat Med."},{"key":"10.1016\/j.rgmxen.2024.10.009_bib0505","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1038\/s41467-017-01403-9","article-title":"Identification of an analgesic lipopeptide produced by the probiotic Escherichia coli strain Nissle 1917","volume":"8","author":"P\u00e9rez\u2010Berezo","year":"2017","journal-title":"Nat Commun."},{"key":"10.1016\/j.rgmxen.2024.10.009_bib0510","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1053\/j.gastro.2004.11.050","article-title":"Lactobacillus and bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles","volume":"128","author":"O\u2019Mahony","year":"2005","journal-title":"Gastroenterology."},{"key":"10.1016\/j.rgmxen.2024.10.009_bib0515","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1111\/j.1572-0241.2006.00734.x","article-title":"Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women\u202fwith irritable bowel syndrome","volume":"101","author":"Whorwell","year":"2006","journal-title":"Am J Gastroenterol."},{"key":"10.1016\/j.rgmxen.2024.10.009_bib0520","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1053\/gast.2001.27224","article-title":"Probiotic bacteria enhance murine and human intestinal epithelial barrier function","volume":"121","author":"Madsen","year":"2001","journal-title":"Gastroenterology."},{"key":"10.1016\/j.rgmxen.2024.10.009_bib0525","article-title":"Escherichia coli Nissle 1917 restores epithelial permeability alterations induced by irritable bowel syndrome mediators","volume":"28","author":"Barbaro","year":"2018","journal-title":"Neurogastroenterol Motil."},{"key":"10.1016\/j.rgmxen.2024.10.009_bib0530","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2017.05.003","article-title":"Probiotic Bifidobacterium longum NCC3001 reduces depression scores and alters brain activity: a pilot study in patients with irritable bowel syndrome","volume":"153","author":"Pinto\u2010S\u00e1nchez","year":"2017","journal-title":"Gastroenterology."},{"key":"10.1016\/j.rgmxen.2024.10.009_bib0535","unstructured":"Guarner F, Sanders ME, Kaufmann P, et al. World Gastroenterology Organization. World Gastroenterology Organisation Global Guidelines: probiotics and prebiotics. 2017 [accessed 11 Nov 2024]. Available from: www.worldgastroenterology.org\/probiotics-prebiotics.html."},{"key":"10.1016\/j.rgmxen.2024.10.009_bib0540","doi-asserted-by":"crossref","first-page":"17","DOI":"10.14309\/ajg.0000000000001036","article-title":"ACG Clinical Guideline: management of irritable bowel syndrome","volume":"116","author":"Lacy","year":"2021","journal-title":"Am J Gastroenterol."},{"key":"10.1016\/j.rgmxen.2024.10.009_bib0545","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1053\/j.gastro.2020.05.059","article-title":"AGA Clinical practice guidelines on the role of probiotics in the management of gastrointestinal disorders","volume":"159","author":"Su","year":"2020","journal-title":"Gastroenterology."},{"key":"10.1016\/j.rgmxen.2024.10.009_bib0550","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1136\/gutjnl-2021-324598","article-title":"British Society of Gastroenterology guidelines on the management of irritable bowel syndrome","volume":"70","author":"Vasant","year":"2021","journal-title":"Gut."},{"key":"10.1016\/j.rgmxen.2024.10.009_bib0555","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1093\/jcag\/gwy071","article-title":"Canadian Association of Gastroenterology Clinical Practice Guideline for the Management of Irritable Bowel Syndrome (IBS)","volume":"2","author":"Moayyedi","year":"2019","journal-title":"J Can Assoc Gastroenterol."},{"key":"10.1016\/j.rgmxen.2024.10.009_bib0560","first-page":"156","article-title":"The Mexican consensus on probiotics in gastroenterology","volume":"82","author":"Valdovinos","year":"2017","journal-title":"Rev Gastroenterol Mex."},{"key":"10.1016\/j.rgmxen.2024.10.009_bib0565","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.3390\/nu16132114","article-title":"The efficacy of probiotics, prebiotics, synbiotics, and fecal microbiota transplantation in irritable bowel syndrome: a systematic review and network meta-analysis","volume":"16","author":"Wu","year":"2024","journal-title":"Nutrients."},{"key":"10.1016\/j.rgmxen.2024.10.009_bib0570","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1111\/apt.15001","article-title":"Systematic review with meta-analysis: the efficacy of prebiotics, probiotics, synbiotics and antibiotics in irritable bowel syndrome","volume":"48","author":"Ford","year":"2018","journal-title":"Aliment Pharmacol Ther."},{"key":"10.1016\/j.rgmxen.2024.10.009_bib0575","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1111\/j.1572-0241.2006.00734.x","article-title":"Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome","volume":"101","author":"Whorwell","year":"2006","journal-title":"Am J Gastroenterol."},{"key":"10.1016\/j.rgmxen.2024.10.009_bib0580","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1177\/2050640615602571","article-title":"Randomized double-blind placebo-controlled trial of Saccharomcyces cerevisiae CNCM I-3856 in irritable bowel syndrome: Improvement in abdominal pain and bloating in those with predominant constipation","volume":"4","author":"Spiller","year":"2016","journal-title":"United Eur Gastroenterol J."},{"key":"10.1016\/j.rgmxen.2024.10.009_bib0585","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2019.10.036","article-title":"Use of treatments for irritable bowel syndrome and patient satisfaction based on the IBS in America Survey","volume":"158","author":"Rangan","year":"2020","journal-title":"Gastroenterology."},{"key":"10.1016\/j.rgmxen.2024.10.009_bib0590","first-page":"303","article-title":"Probiotic use in clinical practice: results of a national survey of gastroenterologists and nutritionists","volume":"84","author":"Valdovinos-Garc\u00eda","year":"2019","journal-title":"Rev Gastroenterol Mex."},{"key":"10.1016\/j.rgmxen.2024.10.009_bib0595","doi-asserted-by":"crossref","DOI":"10.1093\/mmy\/myad014","article-title":"Epidemiology of Saccharomyces fungemia: a systematic review","volume":"61","author":"Vinayagamoorthy","year":"2023","journal-title":"Med Mycol."},{"key":"10.1016\/j.rgmxen.2024.10.009_bib0600","doi-asserted-by":"crossref","first-page":"53","DOI":"10.3390\/antibiotics13010053","article-title":"Infective endocarditis by Lactobacillus species-a narrative review","volume":"13","author":"Ioannou","year":"2024","journal-title":"Antibiotics (Basel)."},{"key":"10.1016\/j.rgmxen.2024.10.009_bib0605","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/s41424-018-0030-7","article-title":"Brain fogginess, gas and bloating: a link between SIBO, probiotics and metabolic acidosis","volume":"9","author":"Rao","year":"2018","journal-title":"Clin Transl Gastroenterol."},{"key":"10.1016\/j.rgmxen.2024.10.009_bib0610","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1159\/000485410","article-title":"STW 5 (Iberogast) Therapy in gastrointestinal functional disorders","volume":"35","author":"Malfertheiner","year":"2017","journal-title":"Dig Dis."},{"key":"10.1016\/j.rgmxen.2024.10.009_bib0615","doi-asserted-by":"crossref","first-page":"601","DOI":"10.3389\/fpsyt.2020.00601","article-title":"Herbal therapies in functional gastrointestinal disorders: a narrative review and clinical implication","volume":"11","author":"Kim","year":"2020","journal-title":"Front Psychiatry."},{"key":"10.1016\/j.rgmxen.2024.10.009_bib0620","doi-asserted-by":"crossref","first-page":"227","DOI":"10.15403\/jgld-814","article-title":"Multi-target treatment for irritable bowel syndrome with STW 5: pharmacological modes of action","volume":"29","author":"Allescher","year":"2020","journal-title":"J Gastrointestin Liver Dis."},{"key":"10.1016\/j.rgmxen.2024.10.009_bib0625","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1159\/000485456","article-title":"Mechanism of action of stw 5 in functional dyspepsia and ibs: the origin of multi-target","volume":"35","author":"Allescher","year":"2017","journal-title":"Dig Dis."},{"key":"10.1016\/j.rgmxen.2024.10.009_bib0630","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.phymed.2006.08.004","article-title":"Spasmolytic and tonic effect of Iberogast (STW 5) in intestinal smooth muscle","volume":"13","author":"Ammon","year":"2006","journal-title":"Phytomedicine."},{"key":"10.1016\/j.rgmxen.2024.10.009_bib0635","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1111\/j.1365-2982.2008.01242.x","article-title":"The multi-herbal drug STW 5 (Iberogast) has prosecretory action in the human intestine","volume":"21","author":"Krueger","year":"2009","journal-title":"Neurogastroenterol Motil."},{"key":"10.1016\/j.rgmxen.2024.10.009_bib0640","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.phymed.2008.10.011","article-title":"Inhibition of inflammation-induced alterations in rat small intestine by the herbal preparations STW 5 and STW 6","volume":"16","author":"Michael","year":"2009","journal-title":"Phytomedicine."},{"key":"10.1016\/j.rgmxen.2024.10.009_bib0645","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1111\/j.1365-2982.2004.00576.x","article-title":"The herbal preparation STW 5 (Iberogast) desensitizes intestinal afferents in the rat small intestine","volume":"16","author":"Liu","year":"2004","journal-title":"Neurogastroenterol Motil."},{"key":"10.1016\/j.rgmxen.2024.10.009_bib0650","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1186\/s12906-021-03337-8","article-title":"Effect of the standard herbal preparation, STW5, treatment on dysbiosis induced by dextran sodium sulfate in experimental colitis","volume":"21","author":"Mohamed","year":"2021","journal-title":"BMC Complement Med Ther."},{"key":"10.1016\/j.rgmxen.2024.10.009_bib0655","doi-asserted-by":"crossref","DOI":"10.1016\/j.phymed.2023.154996","article-title":"Possible role of the gut microbiome in mediating the beneficial effects of the six-herbal formulation STW 5-II on digestive health","volume":"119","author":"Ammar","year":"2023","journal-title":"Phytomedicine."},{"key":"10.1016\/j.rgmxen.2024.10.009_bib0660","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1002\/ptr.6664","article-title":"Ethnomedicinal, phytochemical and pharmacological updates on Peppermint (Mentha \u00d7 piperita L.)\u2013a review","volume":"34","author":"Mahendran","year":"2020","journal-title":"Phytother Res."},{"key":"10.1016\/j.rgmxen.2024.10.009_bib0665","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.113559","article-title":"Peppermint essential oil: its phytochemistry, biological activity, pharmacological effect and application","volume":"154","author":"Zhao","year":"2022","journal-title":"Biomed Pharmacother."},{"key":"10.1016\/j.rgmxen.2024.10.009_bib0670","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.phytochem.2013.08.005","article-title":"Menthol: a simple monoterpene with remarkable biological properties","volume":"96","author":"Kamatou","year":"2013","journal-title":"Phytochemistry."},{"key":"10.1016\/j.rgmxen.2024.10.009_bib0675","doi-asserted-by":"crossref","DOI":"10.1016\/j.toxicon.2023.107309","article-title":"Peppermint essential oil and its nano-emulsion: potential against aflatoxigenic fungus Aspergillus flavus in food and feed","volume":"234","author":"Abd El-Hack","year":"2023","journal-title":"Toxicon."},{"key":"10.1016\/j.rgmxen.2024.10.009_bib0680","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1111\/cts.13224","article-title":"Peppermint oil effects on the gut microbiome in children with functional abdominal pain","volume":"15","author":"Thapa","year":"2022","journal-title":"Clin Transl Sci."},{"key":"10.1016\/j.rgmxen.2024.10.009_bib0685","doi-asserted-by":"crossref","first-page":"988","DOI":"10.3390\/biom10070988","article-title":"Bioactive natural compounds and antioxidant activity of essential oils from spice plants: new findings and potential applications","volume":"10","author":"Diniz do Nascimento","year":"2020","journal-title":"Biomolecules."},{"key":"10.1016\/j.rgmxen.2024.10.009_bib0690","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1111\/apt.14519","article-title":"Review article: the physiological effects and safety of peppermint oil and its efficacy in irritable bowel syndrome and other functional disorders","volume":"47","author":"Chumpitazi","year":"2018","journal-title":"Aliment Pharmacol Ther."},{"key":"10.1016\/j.rgmxen.2024.10.009_bib0695","doi-asserted-by":"crossref","first-page":"576","DOI":"10.2174\/1381612829666230328163449","article-title":"The use of peppermint oil in gastroenterology","volume":"29","author":"Scarpellini","year":"2023","journal-title":"Curr Pharm Des."},{"key":"10.1016\/j.rgmxen.2024.10.009_bib0700","doi-asserted-by":"crossref","first-page":"S63","DOI":"10.1111\/apt.16625","article-title":"Review Article: current and future treatment approaches for IBS with diarrhoea (IBS-D) and IBS mixed pattern (IBS-M)","volume":"54","author":"Nee","year":"2021","journal-title":"Aliment Pharmacol Ther."},{"key":"10.1016\/j.rgmxen.2024.10.009_bib0705","doi-asserted-by":"crossref","first-page":"346","DOI":"10.3748\/wjg.v20.i2.346","article-title":"Complementary and alternative medicines in irritable bowel syndrome: an integrative view","volume":"20","author":"Grundmann","year":"2014","journal-title":"World J Gastroenterol."},{"key":"10.1016\/j.rgmxen.2024.10.009_bib0710","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1111\/j.1365-2036.2004.01859.x","article-title":"Treatment of irritable bowel syndrome with herbal preparations: results of a double-blind, randomized, placebo-controlled, multi-centre trial","volume":"19","author":"Madisch","year":"2004","journal-title":"Aliment Pharmacol Ther."},{"key":"10.1016\/j.rgmxen.2024.10.009_bib0715","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s10354-012-0169-x","article-title":"STW 5 (Iberogast\u00ae)\u2013a safe and effective standard in the treatment of functional gastrointestinal disorders","volume":"163","author":"Ottillinger","year":"2013","journal-title":"Wien Med Wochenschr."},{"key":"10.1016\/j.rgmxen.2024.10.009_bib0720","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctim.2019.102233","article-title":"Western herbal medicines in the treatment of irritable bowel syndrome: a systematic review and meta-analysis","volume":"48","author":"Hawrelak","year":"2020","journal-title":"Complement Ther Med."},{"key":"10.1016\/j.rgmxen.2024.10.009_bib0725","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1111\/jgh.14905","article-title":"Herbal medicine in the treatment of functional gastrointestinal disorders: a systematic review with meta-analysis","volume":"35","author":"Tan","year":"2020","journal-title":"J Gastroenterol Hepatol."},{"key":"10.1016\/j.rgmxen.2024.10.009_bib0730","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1097\/MCG.0b013e3182a88357","article-title":"Peppermint oil for the treatment of irritable bowel syndrome: a systematic review and meta-analysis","volume":"48","author":"Khanna","year":"2014","journal-title":"J Clin Gastroenterol."},{"key":"10.1016\/j.rgmxen.2024.10.009_bib0735","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s12906-018-2409-0","article-title":"The impact of peppermint oil on the irritable bowel syndrome: a meta-analysis of the pooled clinical data","volume":"19","author":"Alammar","year":"2019","journal-title":"BMC Complement Altern Med."},{"key":"10.1016\/j.rgmxen.2024.10.009_bib0740","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1111\/apt.17179","article-title":"Systematic review and meta-analysis: efficacy of peppermint oil in irritable bowel syndrome","volume":"56","author":"Ingrosso","year":"2022","journal-title":"Aliment Pharmacol Ther."},{"key":"10.1016\/j.rgmxen.2024.10.009_bib0745","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1053\/j.gastro.2019.08.026","article-title":"Efficacy and safety of peppermint oil in a randomized, double-blind trial of patients with irritable bowel syndrome","volume":"158","author":"Weerts","year":"2020","journal-title":"Gastroenterology."},{"key":"10.1016\/j.rgmxen.2024.10.009_bib0750","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.14309\/ajg.0000000000001395","article-title":"Peppermint oil treatment for irritable bowel syndrome: a randomized placebo-controlled trial","volume":"116","author":"Nee","year":"2021","journal-title":"Am J Gastroenterol."},{"key":"10.1016\/j.rgmxen.2024.10.009_bib0755","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1002\/ueg2.12134","article-title":"A trial-based economic evaluation of peppermint oil for the treatment of irritable bowel syndrome","volume":"9","author":"Weerts","year":"2021","journal-title":"United Eur Gastroenterol J."},{"key":"10.1016\/j.rgmxen.2024.10.009_bib0760","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1159\/000485411","article-title":"Herbal preparation STW 5 for functional gastrointestinal disorders: clinical experience in everyday practice","volume":"35","author":"Lapina","year":"2017","journal-title":"Dig Dis."},{"key":"10.1016\/j.rgmxen.2024.10.009_bib0765","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/S1665-2681(19)31408-5","article-title":"Greater celandine hepatotoxicity: a clinical review","volume":"11","author":"Teschke","year":"2012","journal-title":"Ann Hepatol."},{"key":"10.1016\/j.rgmxen.2024.10.009_bib0770","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1038\/ajg.2016.260","article-title":"Iberogast-induced severe hepatotoxicity leading to liver transplantation","volume":"111","author":"S\u00e1ez-Gonz\u00e1lez","year":"2016","journal-title":"Am J Gastroenterol."},{"key":"10.1016\/j.rgmxen.2024.10.009_bib0775","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2017.11.279","article-title":"Neuromodulators for functional gastrointestinal disorders (disorders of gut-brain interaction): a Rome Foundation working team report","volume":"154","author":"Drossman","year":"2018","journal-title":"Gastroenterology."},{"key":"10.1016\/j.rgmxen.2024.10.009_bib0780","doi-asserted-by":"crossref","first-page":"2933","DOI":"10.3390\/jcm9092933","article-title":"Shortcomings of trials assessing antidepressants in the management of irritable bowel syndrome: a critical review","volume":"9","author":"Oh","year":"2020","journal-title":"J Clin Med."},{"key":"10.1016\/j.rgmxen.2024.10.009_bib0785","article-title":"A systematic review on the efficacy and safety of selective serotonin reuptake inhibitors in gastrointestinal motility disorders: more control, less risk","volume":"14","author":"Acharekar","year":"2022","journal-title":"Cureus."},{"key":"10.1016\/j.rgmxen.2024.10.009_bib0790","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.3390\/molecules27051680","article-title":"The role of serotonin neurotransmission in gastrointestinal tract and pharmacotherapy","volume":"27","author":"Guzel","year":"2022","journal-title":"Molecules."},{"key":"10.1016\/j.rgmxen.2024.10.009_bib0795","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1016\/j.mayocp.2018.04.032","article-title":"Management options for irritable bowel syndrome","volume":"93","author":"Camilleri","year":"2018","journal-title":"Mayo Clin Proc."},{"key":"10.1016\/j.rgmxen.2024.10.009_bib0800","series-title":"UpdateIn: StatPearls","article-title":"Selective serotonin reuptake inhibitors","author":"Chu","year":"2023"},{"key":"10.1016\/j.rgmxen.2024.10.009_bib0805","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1111\/j.1365-2036.2006.02724.x","article-title":"Influence of acute serotonin reuptake inhibition on colonic sensorimotor function in man","volume":"23","author":"Tack","year":"2006","journal-title":"Aliment Pharmacol Ther."},{"key":"10.1016\/j.rgmxen.2024.10.009_bib0810","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/00003088-199700321-00003","article-title":"Clinically relevant pharmacology of selective serotonin reuptake inhibitors. An overview with emphasis on pharmacokinetics and effects on oxidative drug metabolism","volume":"32","author":"Preskorn","year":"1997","journal-title":"Clin Pharmacokinet."},{"key":"10.1016\/j.rgmxen.2024.10.009_bib0815","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1111\/j.1572-0241.2004.04127.x","article-title":"Paroxetine to treat irritable bowel syndrome not responding to high-fiber diet: a double-blind, placebo-controlled trial","volume":"99","author":"Tabas","year":"2004","journal-title":"Am J Gastroenterol."},{"key":"10.1016\/j.rgmxen.2024.10.009_bib0820","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1111\/j.1365-2036.2005.02566.x","article-title":"The effect of fluoxetine in patients with pain and constipation predominant irritable bowel syndrome: a double-blind randomized-controlled study","volume":"22","author":"Vahedi","year":"2005","journal-title":"Aliment Pharmacol Ther."},{"key":"10.1016\/j.rgmxen.2024.10.009_bib0825","doi-asserted-by":"crossref","first-page":"959","DOI":"10.4088\/JCP.v65n0712","article-title":"Incidence and duration of side effects and those rated as bothersome with selective serotonin reuptake inhibitor treatment for depression: patient report versus physician estimate","volume":"65","author":"Hu","year":"2004","journal-title":"J Clin Psychiatry."},{"key":"10.1016\/j.rgmxen.2024.10.009_bib0830","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1177\/1060028013501994","article-title":"A comparison of the risk of QT prolongation among SSRIs","volume":"47","author":"Funk","year":"2013","journal-title":"Ann Pharmacother."},{"key":"10.1016\/j.rgmxen.2024.10.009_bib0835","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.14309\/ajg.0000000000002800","article-title":"Central neuromodulators in irritable bowel syndrome: why, how, and when","volume":"119","author":"Hanna-Jairala","year":"2024","journal-title":"Am J Gastroenterol."},{"key":"10.1016\/j.rgmxen.2024.10.009_bib0840","doi-asserted-by":"crossref","first-page":"419","DOI":"10.2169\/internalmedicine.52.9147","article-title":"A meta-analysis of the therapeutic effects of amitriptyline for treating irritable bowel syndrome","volume":"52","author":"Chao","year":"2013","journal-title":"Intern Med."},{"key":"10.1016\/j.rgmxen.2024.10.009_bib0845","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.3748\/wjg.15.1548","article-title":"Efficacy of tricyclic antidepressants in irritable bowel syndrome: a meta-analysis","volume":"15","author":"Rahimi","year":"2009","journal-title":"World J Gastroenterol."},{"key":"10.1016\/j.rgmxen.2024.10.009_bib0850","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/s41395-018-0222-5","article-title":"Effect of antidepressants and psychological therapies in irritable bowel syndrome: an updated systematic review and meta-analysis","volume":"114","author":"Ford","year":"2019","journal-title":"Am J Gastroenterol."},{"key":"10.1016\/j.rgmxen.2024.10.009_bib0855","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1016\/S0140-6736(23)01523-4","article-title":"Amitriptyline at low-dose and titrated for irritable bowel syndrome as second-line treatment in primary care (ATLANTIS): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"402","author":"Ford","year":"2023","journal-title":"Lancet."},{"key":"10.1016\/j.rgmxen.2024.10.009_bib0860","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1016\/j.pharep.2017.05.014","article-title":"Antidepressants for irritable bowel syndrome\u2013a systematic review","volume":"69","author":"Kulak-Bejda","year":"2017","journal-title":"Pharmacol Rep."},{"key":"10.1016\/j.rgmxen.2024.10.009_bib0865","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1111\/j.1527-3458.2001.tb00198.x","article-title":"A review of the pharmacological and clinical profile of mirtazapine","volume":"7","author":"Anttila","year":"2006","journal-title":"CNS Drug Rev."},{"key":"10.1016\/j.rgmxen.2024.10.009_bib0870","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1093\/ajhp\/55.1.44","article-title":"Mirtazapine, an antidepressant","volume":"55","author":"Puzantian","year":"1998","journal-title":"Am J Health Syst Pharm."},{"key":"10.1016\/j.rgmxen.2024.10.009_bib0875","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s13030-021-00205-2","article-title":"A randomized, double-blind, placebo-controlled study to assess efficacy of mirtazapine for the treatment of diarrhea predominant irritable bowel syndrome","volume":"15","author":"Khalilian","year":"2021","journal-title":"Biopsychosoc Med."},{"key":"10.1016\/j.rgmxen.2024.10.009_bib0880","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1097\/WNF.0b013e318209cef2","article-title":"Treatment of irritable bowel syndrome with comorbid anxiety symptoms with mirtazapine","volume":"34","author":"Spiegel","year":"2011","journal-title":"Clin Neuropharmacol."},{"key":"10.1016\/j.rgmxen.2024.10.009_bib0885","first-page":"17","article-title":"Mirtazapine in diarrhea-predominant irritable bowel syndrome: an open-label study","volume":"3","author":"Sanagapalli","year":"2018","journal-title":"J Gastroenterol Dig Dis."},{"key":"10.1016\/j.rgmxen.2024.10.009_bib0890","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/164_2018_164","article-title":"Serotonin and norepinephrine reuptake inhibitors","volume":"250","author":"Shelton","year":"2019","journal-title":"Handb Exp Pharmacol."},{"key":"10.1016\/j.rgmxen.2024.10.009_bib0895","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1002\/hup.1038","article-title":"Duloxetine in the treatment of irritable bowel syndrome: an open-label pilot study","volume":"24","author":"Brennan","year":"2009","journal-title":"Hum Psychopharmacol."},{"key":"10.1016\/j.rgmxen.2024.10.009_bib0900","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3109\/13651501.2013.838632","article-title":"An open-label trial of duloxetine in patients with irritable bowel syndrome and comorbid generalized anxiety disorder","volume":"18","author":"Kaplan","year":"2014","journal-title":"Int J Psychiatry Clin Pract."},{"key":"10.1016\/j.rgmxen.2024.10.009_bib0905","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1097\/JCP.0000000000000599","article-title":"An open-label pilot study of duloxetine in patients with irritable bowel syndrome and comorbid major depressive disorder","volume":"36","author":"Lewis-Fern\u00e1ndez","year":"2016","journal-title":"J Clin Psychopharmacol."},{"key":"10.1016\/j.rgmxen.2024.10.009_bib0910","first-page":"45","article-title":"Comparison of fluoxetine and duloxetine hydrochloride therapeutic effects on patients with constipation-predominant irritable bowel syndrome","volume":"15","author":"Jafari","year":"2022","journal-title":"Gastroenterol Hepatol Bed Bench."},{"key":"10.1016\/j.rgmxen.2024.10.009_bib0915","doi-asserted-by":"crossref","first-page":"14","DOI":"10.4103\/abr.abr_247_20","article-title":"Investigation the effectiveness of duloxetine in quality of life and symptoms of patients with irritable bowel syndrome","volume":"28","author":"Salehian","year":"2021","journal-title":"Adv Biomed Res."},{"key":"10.1016\/j.rgmxen.2024.10.009_bib0920","doi-asserted-by":"crossref","first-page":"115","DOI":"10.4103\/jrms.JRMS_699_19","article-title":"P. Effects of venlafaxine on gastrointestinal symptoms, depression, anxiety, stress, and quality of life in patients with the moderate-to-severe irritable bowel syndrome","volume":"25","author":"Sharbafchi","year":"2020","journal-title":"J Res Med Sci."},{"key":"10.1016\/j.rgmxen.2024.10.009_bib0925","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1007\/s40263-012-0010-5","article-title":"Rediscovering trazodone for the treatment of major depressive disorder","volume":"26","author":"Fagiolini","year":"2012","journal-title":"CNS Drugs."},{"key":"10.1016\/j.rgmxen.2024.10.009_bib0930","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1136\/gut.2006.110858","article-title":"Effect of a second-generation alpha2delta ligand (pregabalin) on visceral sensation in hypersensitive patients with irritable bowel syndrome","volume":"56","author":"Houghton","year":"2007","journal-title":"Gut."},{"key":"10.1016\/j.rgmxen.2024.10.009_bib0935","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1136\/gut.2007.127514","article-title":"alpha2delta ligand: a new, smart pill for visceral pain in patients with hypersensitive irritable bowel syndrome?","volume":"56","author":"Camilleri","year":"2007","journal-title":"Gut."},{"key":"10.1016\/j.rgmxen.2024.10.009_bib0940","doi-asserted-by":"crossref","DOI":"10.1111\/nmo.14305","article-title":"Pain in irritable bowel syndrome: does anything really help?","volume":"34","author":"BouSaba","year":"2022","journal-title":"Neurogastroenterol Motil."},{"key":"10.1016\/j.rgmxen.2024.10.009_bib0945","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.dld.2013.09.002","article-title":"Pilot trial: pregabalin on colonic sensorimotor functions in irritable bowel syndrome","volume":"46","author":"Iturrino","year":"2014","journal-title":"Dig Liver Dis."},{"key":"10.1016\/j.rgmxen.2024.10.009_bib0950","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1111\/apt.15077","article-title":"Randomised clinical trial: pregabalin vs placebo for irritable bowel syndrome","volume":"49","author":"Saito","year":"2019","journal-title":"Aliment Pharmacol Ther."},{"key":"10.1016\/j.rgmxen.2024.10.009_bib0955","doi-asserted-by":"crossref","DOI":"10.1111\/nmo.14289","article-title":"Oral and parenteral anti-neuropathic agents for the management of pain and discomfort in irritable bowel syndrome: a systematic review and meta-analysis","volume":"34","author":"Lambarth","year":"2022","journal-title":"Neurogastroenterol Motil."},{"key":"10.1016\/j.rgmxen.2024.10.009_bib0960","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/j.pnpbp.2010.03.014","article-title":"Quetiapine in the treatment of refractory irritable bowel syndrome: a case report","volume":"34","author":"Mart\u00edn-Blanco","year":"2010","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry."},{"key":"10.1016\/j.rgmxen.2024.10.009_bib0965","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.gtc.2021.04.005","article-title":"Psychopharmacologic therapies for irritable bowel syndrome","volume":"50","author":"T\u00f6rnblom","year":"2021","journal-title":"Gastroenterol Clin North Am."},{"key":"10.1016\/j.rgmxen.2024.10.009_bib0970","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1517\/13543784.2013.782392","article-title":"Atypical antipsychotics as a possible treatment option for irritable bowel syndrome","volume":"22","author":"Pae","year":"2013","journal-title":"Expert Opin Investig Drugs."},{"key":"10.1016\/j.rgmxen.2024.10.009_bib0975","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1007\/s10620-009-0723-6","article-title":"Atypical antipsychotic quetiapine in the management of severe refractory functional gastrointestinal disorders","volume":"54","author":"Grover","year":"2009","journal-title":"Dig Dis Sci."},{"key":"10.1016\/j.rgmxen.2024.10.009_bib0980","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1097\/JCP.0b013e318267b8ca","article-title":"Add-on treatment of quetiapine for fibromyalgia: a pilot, randomized, double-blind, placebo-controlled 12-week trial","volume":"32","author":"Potvin","year":"2012","journal-title":"J Clin Psychopharmacol."},{"key":"10.1016\/j.rgmxen.2024.10.009_bib0985","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/s00213-003-1759-5","article-title":"Sleep-promoting properties of quetiapine in healthy subjects","volume":"174","author":"Cohrs","year":"2004","journal-title":"Psychopharmacology (Berl)."},{"key":"10.1016\/j.rgmxen.2024.10.009_bib0990","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1007\/BF00607085","article-title":"Inhibition of postprandial colonic motility by sulpiride in patients with irritable colon","volume":"24","author":"Lanfranchi","year":"1983","journal-title":"Eur J Clin Pharmacol."},{"key":"10.1016\/j.rgmxen.2024.10.009_bib0995","first-page":"618","article-title":"Efficacy of prokinetic agents in diabetic gastroparesis comparing symptomatology and scintigraphy - an open-label trial","volume":"14","author":"Kant","year":"2023","journal-title":"Caspian J Intern Med."},{"key":"10.1016\/j.rgmxen.2024.10.009_bib1000","first-page":"22","article-title":"Sulpiride treatment of irritable colon syndrome","volume":"78","author":"Komarov","year":"2000","journal-title":"Klin Med (Mosk)."},{"key":"10.1016\/j.rgmxen.2024.10.009_bib1005","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1159\/000079104","article-title":"Consensus on the use of substituted benzamides in psychiatric patients","volume":"50","author":"Racagni","year":"2004","journal-title":"Neuropsychobiology."},{"key":"10.1016\/j.rgmxen.2024.10.009_bib1010","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1136\/jrnms-46-30","article-title":"Clinical trial in peptic ulceration of \u201cstelabid\u201d, a combination of trifluoperazine (stelazine) and isopropamide iodine (tyrimide)","volume":"46","author":"Arden","year":"1960","journal-title":"J R Nav Med Serv."},{"key":"10.1016\/j.rgmxen.2024.10.009_bib1015","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1111\/j.1742-1241.1960.tb05838.x","article-title":"Treatment of dyspepsia with a combination of trifluoperazine and isopropamide iodide","volume":"14","author":"Platt","year":"1960","journal-title":"Br J Clin Pract."},{"key":"10.1016\/j.rgmxen.2024.10.009_bib1020","first-page":"96","article-title":"Microbiota, gastrointestinal infections, low-grade inflammation, and antibiotic therapy in irritable bowel syndrome: an evidence-based review","volume":"79","author":"Schmulson","year":"2014","journal-title":"Rev Gastroenterol Mex."},{"key":"10.1016\/j.rgmxen.2024.10.009_bib1025","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1084\/jem.20041948","article-title":"Intestinal antiinflammatory effect of 5-aminosalicylic acid is dependent on peroxisome proliferator-activated receptor-gamma","volume":"201","author":"Rousseaux","year":"2005","journal-title":"J Exp Med."},{"key":"10.1016\/j.rgmxen.2024.10.009_bib1030","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/BF01300753","article-title":"Modulation of mediator release from human intestinal mast cells by sulfasalazine and 5-aminosalicylic acid","volume":"36","author":"Fox","year":"1991","journal-title":"Dig Dis Sci."},{"key":"10.1016\/j.rgmxen.2024.10.009_bib1035","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1111\/j.1365-2036.2009.04041.x","article-title":"Effect of mesalazine on mucosal immune biomarkers in irritable bowel syndrome: a randomized controlled proof-of-concept study","volume":"30","author":"Corinaldesi","year":"2009","journal-title":"Aliment Pharmacol Ther."},{"key":"10.1016\/j.rgmxen.2024.10.009_bib1040","doi-asserted-by":"crossref","DOI":"10.1016\/j.cgh.2023.02.014","article-title":"Systematic review and meta-analysis: efficacy of mesalamine in irritable bowel syndrome","volume":"22","author":"Goodoory","year":"2024","journal-title":"Clin Gastroenterol Hepatol."},{"key":"10.1016\/j.rgmxen.2024.10.009_bib1045","doi-asserted-by":"crossref","DOI":"10.1111\/nmo.14889","article-title":"Randomized double-blind placebo-controlled study to evaluate the effect of long-acting mesalamine on postinfectious irritable bowel syndrome with diarrhea","author":"Tuteja","year":"2024","journal-title":"Neurogastroenterol Motil."}],"container-title":["Revista de Gastroenterolog\u00eda de M\u00e9xico (English Edition)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2255534X25000155?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2255534X25000155?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,10]],"date-time":"2025-05-10T05:17:39Z","timestamp":1746854259000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2255534X25000155"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":209,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["S2255534X25000155"],"URL":"https:\/\/doi.org\/10.1016\/j.rgmxen.2024.10.009","relation":{},"ISSN":["2255-534X"],"issn-type":[{"value":"2255-534X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacologic treatment of irritable bowel syndrome. Position statement of the Asociaci\u00f3n Mexicana de Gastroenterolog\u00eda, 2024","name":"articletitle","label":"Article Title"},{"value":"Revista de Gastroenterolog\u00eda de M\u00e9xico (English Edition)","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rgmxen.2024.10.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Masson Doyma M\u00e9xico S.A. on behalf of Asociaci\u00f3n Mexicana de Gastroenterolog\u00eda.","name":"copyright","label":"Copyright"}]}}